|
Hikma Pharmaceuticals plc (hik.l) Avaliação DCF
GB | Healthcare | Drug Manufacturers - Specialty & Generic | LSE
|
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Hikma Pharmaceuticals PLC (HIK.L) Bundle
Descubra o verdadeiro valor da Hikma Pharmaceuticals plc (HIKL) com nossa calculadora DCF de nível profissional! Ajuste as principais suposições, explore vários cenários e avalie como as mudanças afetam a avaliação Hikma Pharmaceuticals PLC (HIKL) - tudo dentro de um único modelo do Excel.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,753.3 | 1,859.7 | 2,028.2 | 1,999.6 | 2,284.0 | 2,443.5 | 2,614.2 | 2,796.8 | 2,992.1 | 3,201.2 |
| Revenue Growth, % | 0 | 6.07 | 9.06 | -1.41 | 14.22 | 6.99 | 6.99 | 6.99 | 6.99 | 6.99 |
| EBITDA | 463.9 | 519.6 | 591.0 | 385.3 | 628.4 | 636.9 | 681.4 | 729.0 | 779.9 | 834.4 |
| EBITDA, % | 26.46 | 27.94 | 29.14 | 19.27 | 27.51 | 26.06 | 26.06 | 26.06 | 26.06 | 26.06 |
| Depreciation | 78.6 | 72.3 | 114.4 | 153.3 | 136.6 | 135.2 | 144.6 | 154.7 | 165.5 | 177.1 |
| Depreciation, % | 4.49 | 3.89 | 5.64 | 7.67 | 5.98 | 5.53 | 5.53 | 5.53 | 5.53 | 5.53 |
| EBIT | 385.3 | 447.3 | 476.7 | 232.0 | 491.7 | 501.7 | 536.7 | 574.2 | 614.3 | 657.3 |
| EBIT, % | 21.98 | 24.05 | 23.5 | 11.6 | 21.53 | 20.53 | 20.53 | 20.53 | 20.53 | 20.53 |
| Total Cash | 369.4 | 275.7 | 357.5 | 232.0 | 181.9 | 357.2 | 382.1 | 408.8 | 437.4 | 467.9 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 506.0 | 525.9 | 620.4 | 617.3 | 626.8 | 713.7 | 763.6 | 816.9 | 874.0 | 935.0 |
| Account Receivables, % | 28.86 | 28.28 | 30.59 | 30.87 | 27.44 | 29.21 | 29.21 | 29.21 | 29.21 | 29.21 |
| Inventories | 451.2 | 601.4 | 552.1 | 616.5 | 707.8 | 719.0 | 769.2 | 822.9 | 880.4 | 941.9 |
| Inventories, % | 25.74 | 32.34 | 27.22 | 30.83 | 30.99 | 29.42 | 29.42 | 29.42 | 29.42 | 29.42 |
| Accounts Payable | 227.2 | 221.6 | 208.1 | 231.2 | 245.5 | 280.7 | 300.4 | 321.3 | 343.8 | 367.8 |
| Accounts Payable, % | 12.96 | 11.92 | 10.26 | 11.56 | 10.75 | 11.49 | 11.49 | 11.49 | 11.49 | 11.49 |
| Capital Expenditure | -94.5 | -136.6 | -115.2 | -109.6 | -134.3 | -145.5 | -155.7 | -166.6 | -178.2 | -190.7 |
| Capital Expenditure, % | -5.39 | -7.35 | -5.68 | -5.48 | -5.88 | -5.96 | -5.96 | -5.96 | -5.96 | -5.96 |
| Tax Rate, % | 32.38 | 32.38 | 32.38 | 32.38 | 32.38 | 32.38 | 32.38 | 32.38 | 32.38 | 32.38 |
| EBITAT | 381.4 | 345.5 | 368.9 | 187.2 | 332.5 | 403.3 | 431.4 | 461.6 | 493.8 | 528.3 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -364.6 | 105.5 | 309.3 | 192.7 | 248.3 | 330.1 | 339.9 | 363.7 | 389.1 | 416.2 |
| WACC, % | 6.64 | 6.38 | 6.38 | 6.42 | 6.27 | 6.42 | 6.42 | 6.42 | 6.42 | 6.42 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 1,520.4 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 425 | |||||||||
| Terminal Value | 9,605 | |||||||||
| Present Terminal Value | 7,037 | |||||||||
| Enterprise Value | 8,558 | |||||||||
| Net Debt | 783 | |||||||||
| Equity Value | 7,774 | |||||||||
| Diluted Shares Outstanding, MM | 222 | |||||||||
| Equity Value Per Share | 3,496.11 |
What You Will Receive
- Customizable Excel Template: A fully adaptable Excel-based DCF Calculator featuring pre-filled actual HIKL financials.
- Authentic Data: Access to historical data and forward-looking projections (highlighted in the yellow cells).
- Flexible Forecasting: Adjust forecast assumptions such as revenue growth, EBITDA %, and WACC at your discretion.
- Real-Time Calculations: Instantly observe how your inputs affect the valuation of Hikma Pharmaceuticals.
- Professional Resource: Designed for investors, CFOs, consultants, and financial analysts alike.
- User-Friendly Layout: Organized for clarity and ease of navigation, complete with step-by-step guidance.
Key Features
- Comprehensive DCF Calculator: Offers detailed unlevered and levered DCF valuation models specifically tailored for Hikma Pharmaceuticals PLC (HIKL).
- WACC Calculator: Features a pre-built Weighted Average Cost of Capital sheet with adjustable inputs to fit your analysis needs.
- Customizable Forecast Assumptions: Adjust growth rates, capital expenditures, and discount rates to suit your projections.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios specifically for Hikma Pharmaceuticals PLC (HIKL).
- Interactive Dashboard and Charts: Visual representations summarize essential valuation metrics for straightforward analysis.
How It Works
- Step 1: Download the prebuilt Excel template featuring Hikma Pharmaceuticals PLC (HIKL) data.
- Step 2: Review the pre-filled sheets to familiarize yourself with the essential metrics.
- Step 3: Modify forecasts and key assumptions in the editable yellow cells (WACC, growth rates, profit margins).
- Step 4: Instantly see updated results, including the intrinsic value of Hikma Pharmaceuticals PLC (HIKL).
- Step 5: Utilize the outputs to make well-informed investment decisions or to create comprehensive reports.
Why Choose This Calculator for Hikma Pharmaceuticals PLC (HIKL)?
- All-in-One Resource: Incorporates DCF, WACC, and financial ratio analyses seamlessly.
- Flexible Inputs: Modify the yellow-highlighted cells to explore different financial scenarios.
- In-Depth Analysis: Automatically determines Hikma's intrinsic value and Net Present Value.
- Integrated Data: Features historical and projected data for reliable baseline evaluations.
- Expert-Level Tool: Perfect for financial analysts, investors, and business advisors.
Who Can Benefit from This Product?
- Individual Investors: Make informed choices regarding the purchase or sale of Hikma Pharmaceuticals PLC (HIKL) stock.
- Financial Analysts: Enhance valuation methodologies with ready-to-implement financial models tailored for Hikma Pharmaceuticals PLC (HIKL).
- Consultants: Provide clients with professional valuation insights regarding Hikma Pharmaceuticals PLC (HIKL) efficiently and accurately.
- Business Owners: Gain insights into how large pharmaceutical companies like Hikma Pharmaceuticals PLC (HIKL) are valued to inform your own business strategies.
- Finance Students: Master valuation techniques using real-life data and case studies involving Hikma Pharmaceuticals PLC (HIKL).
Components of the Template
- Operating and Balance Sheet Data: Pre-filled historical data and forecasts for Hikma Pharmaceuticals PLC (HIKL), including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for the Weighted Average Cost of Capital (WACC), featuring parameters such as Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Customizable Discounted Cash Flow models that illustrate intrinsic value with comprehensive calculations.
- Financial Statements: Pre-loaded annual and quarterly financial statements to facilitate thorough analysis.
- Key Ratios: Contains profitability, leverage, and efficiency ratios specific to Hikma Pharmaceuticals PLC (HIKL).
- Dashboard and Charts: Visual representations of valuation results and underlying assumptions for easy analysis.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.